Mobile App

Copay

Prescribe OMNARIS with a best-in-class $11 copay program*

Your patients can get affordable relief with the OMNARIS

Qualifying patients pay as low as $11 on every OMNARIS prescription fill, up to 12 times per year.

Savings of up to $50 on each prescription fill, with total annual savings of up to $600 per year.

$11 copay is available to patients with the Relief Is Here card, which you can order from Sunovion ProFile™.

Patients may also print an eCard by visiting
www.OMNARIS.COM.

* Restrictions apply. Maximum savings of up to $50, on up to 12 prescription fills of OMNARIS per calendar year.
See program rules and eligibility requirements

Small Font
Medium Font
Large Font

email

print

Access Physician Resources

  • Request Samples
    & Copay Cards
  • View Medication Guide
  • Submit Medical Inquiries

For Your Patients: AllergyManager Mobile App

With pollen forecasts, symptoms diary, refill reminders, and daily allergy tips. Free from the App Store.

See details

OMNARIS (ciclesonide) Nasal Spray is indicated for the treatment of nasal symptoms associated with seasonal allergic rhinitis in adults and children 6 years of age and older and with perennial allergic rhinitis in adults and adolescents 12 years of age and older.

Important Safety Information

Patients using drugs that suppress the immune system are more susceptible to infections. Chickenpox and measles, for example, can have a more serious or even fatal course in children or adults taking corticosteroids. In clinical studies with OMNARIS Nasal Spray, the development of localized infections of the nose and pharynx with Candida albicans has rarely occurred. Intranasal corticosteroids should be used with caution, if at all, in patients with tuberculosis, untreated fungal or bacterial infections, systemic viral or parasitic infections, or ocular herpes simplex.

Patients who have experienced recent nasal septal ulcers, nasal surgery, or nasal trauma should not use a nasal corticosteroid until healing has occurred.

Rare instances of nasal septum perforation, cataracts, glaucoma, and increased intraocular pressure have been reported following the intranasal application of corticosteroids. Close follow-up is warranted in patients with a change in vision and with a history of glaucoma and/or cataracts.

If recommended doses of intranasal corticosteroids are exceeded, or in susceptible individuals used at recommended dosages, symptoms of hypercorticism may occur. If such changes occur, topical corticosteroids should be discontinued slowly.

Intranasal corticosteroids may cause a reduction in growth velocity when administered to pediatric patients. The growth of pediatric patients receiving intranasal corticosteroids, including OMNARIS Nasal Spray, should be monitored routinely.

The most common side effects that may occur with OMNARIS are headache, epistaxis, nasopharyngitis and ear pain.

References

  • 1. OMNARIS [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc.; May 2010.
  • 2. Meltzer EO. Formulation considerations of intranasal corticosteroids for the treatment of allergic rhinitis. Ann Allergy Asthma Immunol. 2007;98(1):12-21.

© 2011 Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co. Ltd., and is a registered trademark of Dainippon Sumitomo Pharma Co. Ltd.
OMNARIS is a registered trademark of Nycomed GmbH, used with permission.